Continuing the Conversation: Exploring B-cell Maturation Antigen-Targeted Therapies and Managed Care Considerations for Patients With Multiple Myeloma | PTCE Pharmacy Connect
Description
Educational Objectives
- Discuss the differing classes of B-cell maturation antigen-directed therapy for multiple myeloma
- Study the economic burden of multiple myeloma and cost-effective treatment strategies for B-cell maturation antigen-directed treatments
Faculty:
Joseph A. Kalis, PharmD, BCOP
Ambulatory Oncology Pharmacist
UCHealth Hematology/Oncology
Colorado Springs, Colorado
Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA
Director, Pharmacy Cancer Care
Department of Pharmacy
Mayo Clinic
Assistant Professor of Pharmacy
Mayo Clinic College of Medicine and Sciences
Rochester, Minnesota
Joseph A. Kalis, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:
Speakers Bureau: Oncopeptides, GSK
Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, has the following financial relationships with commercial interests to disclose:
Grant/Research Support: AstraZeneza, Janssen
Consultant: BeiGene
Speakers Bureau: Pfizer
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-359-H01-P. The activity is available for CE credit through July 29, 2023.
This educational activity is supported by an educational grant from GlaxoSmithKline.
United States
